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Abstract 
Two newPd(II) complexes of N'-(4-(diethylamino)-2-hydroxybenzylidene)furan-2-
carbohydrazide have been synthesized and characterized by various spectral studies. The 
structure of one the complexes has been determined by single crystal X-ray diffraction studies. 
DNA and protein binding affinity of the synthesized compounds were examined by UV-visible 
and fluorescence titration method. In addition, the in vitro cytotoxicity of the compounds were 
evaluated against A549 (lung cancer) and MCF7 (breast cancer) cell lines using the MTT assay 
method. 
Keywords: Schiff base ligand, Pd(II) complexes, DNA/protin binding and Cytotoxicity. 
Introduction 
Transition metal pincer type complexes have been given a very special attention in 
organometallic and coordination chemistry.[1,2] Interestingly, hydrazone ligands usually create a 
pincer type of coordination similar to the one that is observed in biological systems by way of 
coordination through oxygen and nitrogen atoms. It has also been demonstrated that the 
transition metal complexes of aryl hydrazones have not only been shown to function as 
antibacterial, antiviral and antifungal agents but also have exhibited kinetic stabilities of their 
coordination spheres very similar to biological environment.[3-7] The hydrazones, in addition to 
offering rigidity in a conjugated system, have an NH unit that readily participates in hydrogen 
bonding in addition to being a site for protonation–deprotonation. Like for many other 
complexes, it has also been well-established that the formations of metal-hydrazone complexes 
are important in enhancing the biological activity compared to that of free hydrazones.[8] In the 
process of design and synthesis of transition metal complexes as efficient anticancer drugs, a 
detailed knowledge on the interaction of such complexes with DNA and protein is considered as 
essential.[9-13] As far as the metal complexes are concerned, complexes derived from Pd(II) ion 
have been seen as a potential alternative to Pt(II)  compounds as anticancer agents owing to 
structural and thermodynamic similarities between Pt(II) and Pd(II) complexes. Very recent 
investigations have in fact revealed that some of the Pd(II) complexes exhibit similar or even 
better cytotoxicity than the presently used cisplatin and its analogues.[14-16] This might be due to 
the fact that Pd(II) complexes undergo aquation and ligand exchange reactions 105 times faster 
than the corresponding Pt(II) complexes[17], which has resulted in a number of mixed‐ligand 
Pd(II) complexes being tested as of antitumor drugs.[18-20] Hence, during the course of our 
systematic investigations on the synthesis and biological studies of hydrazone complexes, we 
report herein the synthesis, characterization, crystal structure and biological activities of ONO 
pincer type Pd(II) complexes derived from  N'-(4-(diethylamino)-2-hydroxybenzylidene)furan-2-
carbohydrazide. 
Experimental section 
Meterials and methods 
All the reagents used were of analar or chemically pure grade. Solvents were purified and dried 
according to the literature procedure.[21] The ligand and [PdCl2(PPh3)2] were prepared by 
following previously reported literature methods.[22,23] Melting points of the complexes were 
recorded with the lab India melting point apparatus. Elemental analyses of the complexes were 
done by using Vario EL III CHNS instrument. IR spectra of the ligand and complexes were 
recorded in KBr pellets with a JASCO FT-IR 4100 instrument in the 400-4000 cm-1 range. The 
electronic spectra of the complexes were recorded in DMSO using a JASCO V-630 UV-Vis 
Spectrometer in the 200-800 nm range. The 1H-NMR spectra were recorded in DMSO on a 
Bruker 400 MHz instrument with TMS as the standard. DNA binding, competitive binding 
fluorescence measurements, protein binding[24], cytotoxicity experiments[25] were carried out 
according to the reported procedures. 
Crystallography 
X-ray diffraction experiments on complex 1 were carried out at 100(2) K on a Bruker APEX II 
diffractometer with CCD detector using Mo-Kα radiation (λ = 0.71073 Å). Intensities were 
integrated in SAINT[26] and absorption corrections based on equivalent reflections were applied 
using SADABS.[27] The structure was solved using Superflip[28,29], while X was solved using 
ShelXT[30] and refined against F2 in SHELXL[31,32] using Olex2.[33] All of the non-hydrogen 
atoms were refined anisotropically while all of the hydrogen atoms were located geometrically 
and refined using a riding model. Crystal structure and refinement data are given in Table 1. 
Crystallographic data for complex 1 have been deposited with the Cambridge Crystallographic 
Data Centre as supplementary publication CCDC 1585980. Copies of the data can be obtained 
free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax(+44) 
1223 336033, e-mail: deposit@ccdc.cam.ac.uk]. 
Preparation of ligand 
Preparation of N'-(4-(diethylamino)-2-hydroxybenzylidene)furan-2-carbohydrazide(H2L): 
It was prepared from 2-furoic hydrazide (1.26 g, 0.01 mmol) and 4-diethylaminosalicylaldehyde 
(1.9 g, 0.01 mmol). The mixture was refluxed for 6 h (30 cm3) of methanol, during which a 
yellow precipitate formed. The reaction mixture was then cooled to room temperature and the 
solid formed was filtered. It was then washed with methanol and dried under vacuum. Yield: 95 
%. M.p.:133ºC. Anal.Calc. for C16H19N3O3 (%): C, 63.77; H, 6.36; N, 13.94. Found: C, 63.71; H, 
6.30; N, 13.89. Selected IR bands (cm-1): 3434 (ʋOH), 1634 (ʋC=O), 1634 (ʋC=N), 3208 (ʋNH). λmax, 
nm; 261, 356 (intra ligand transition).1H NMR (DMSO-d6, δ ppm, J Hz, (Fig. S1)): 11.32 (s, 1H, 
˗OH), 8.42 (s, 1H, C =N), 9.61 (s, ˗NH), 7.93 (s, 1H, (Ar-H)), 7.24-7.25 (d, J = 3.2 Hz, 2H, (Ar-
H)), 6.34-6.36 (dd, J = 8.8 Hz, 1H, (Ar-H)), 2.54-2.50 (q, J = 15.6 Hz, 4H, ˗CH2N), 1.09-1.11 (t, 
J = 6.8 Hz, 6H, ˗CH3). 
Synthesis of the complexes 
[PdL(PPh3)] (1) 
0.043 g of H2L (0.143 mmol) was dissolved in methanol (30 cm
3) and [PdCl2(PPh3)2] (0.100 g, 
0.143 mmol) dissolved in hot dichloromethane (30 cm3) was added along with two drops of 
triethylamine. The mixture was heated under reflux for 5 h. The resulting solution was cooled, 
filtered and allowed to stand for three days at room temperature which afforded an orange 
colored compound. It was filtered, washed with petroleum ether (60-80 ºC) to remove traces of 
free triphenylphospine and dried under vacuum. Reddish brown colored single crystals suitable 
for X-ray diffraction studies were obtained on slow evaporation of a methanol/toluene solution 
of the compound. Yield: 81 %. M.p.:157ºC. Anal.Calc. for C34H32N3O3PPd (%): C, 61.13; H, 
4.83; N, 6.29. Found: C, 61.09; H, 4.78; N, 6.21. Selected IR bands (cm-1): 1240 (ʋC˗O), 1598 
(ʋC=N). λmax, nm; 268 (intra ligand transition), 411 (metal to ligand charge transfer transition). 1H 
NMR (DMSO-d6, δ ppm, J Hz, (Fig. S2)): 8.15 (s, 1H, C =N), 6.68-6.69 (dd, J = 3.2 Hz, 2H, 
(Ar-H)), 6.19-6.22 (dd, J = 9.2 Hz, 1H, (Ar-H)), 7.28-7.72 (m, 18H, (Ar-H)), 3.22-3.28 (q, J = 
7.2 Hz, 4H, ˗CH2N), 1.02-1.05 (t, J = 6.8 Hz, 6H, ˗CH3).   
[PdL(AsPh3)] (2) 
This was prepared following a procedure similar to the one described for 1 from H2L (0.038 g, 
0.126 mmol) and [PdCl2(AsPh3)2] (0.100 g, 0.126 mmol). The mixture was heated under reflux 
for 5 h, filtered and allowed to stand for three days at room temperature which afforded orange 
colored crystalline compound. Yield: 74 %. M.p.: 163 ºC. Anal.Calc. for C34H32AsN3O3Pd (%): 
C, 57.36; H, 4.53; N, 5.90. Found: C, 57.31; H, 4.50; N, 5.86. Selected IR bands (cm-1): 1241 
(ʋC˗O), 1597 (ʋC=N). λmax, nm; 263 (intra ligand transition), 415 (metal to ligand charge transfer 
transition). 1H NMR (DMSO-d6, δ ppm, J Hz, (Fig. S3)): 8.15 (s, 1H, C =N), 6.03-6.75 (m, 6H, 
(Ar-H)), 7.30-7.73 (m, 15H, (Ar-H)), 3.25-3.34 (q, J = 7.2 Hz, 4H, ˗CH2N), 1.03-1.08 (t,J = 6.8 
Hz, 6H, ˗CH3). 
Results and discussion 
Synthetic routes for the ligand and its Pd(II) complexes are shown in Scheme 1. The compounds 
are air stable and soluble in chloroform, dichloromethane, methanol, ethanol, 
dimethylformamide and dimethylsulfoxide. 
 
 
 Scheme 1.Preparation routes of the ligand (H2L) and Pd(II) complexes (1 and 2).  
 
Spectral characterization 
The electronic spectrum of the ligand showed two bands in the region around 261-356 nm which 
have been assigned to intra ligand transition.[34,35] In the spectra of the complexes 1 and 2, the 
band around 263-268 nm has been assigned to intra ligand transitions and another band around 
411-415 nm has been attributed to a metal to ligand charge transfer transition (MLCT).[35] The IR 
spectra of the N'-(4-(diethylamino)-2-hydroxybenzylidene)furan-2-carbohydrazide (H2L) and the 
corresponding complexes provided significant information about the metal ligand bonding. A strong 
band observed at 3434 cm-1 in the free ligand due to phenolic -OH stretching had completely 
disappeared in the IR spectra of complexes 1 and 2 indicating deprotonation prior to coordination.[36] 
A strong band in the region 1634 cm-1characteristic of the azomethine group in the free ligand has 
shifted to lower frequency 1598 and 1597 cm-1 for 1 and 2 respectively indicating the coordination of 
azomethine nitrogen atom to the palladium ion.[36] Other characteristic bands due to 
triphenylphospine and triphenylarsine were also observed in the regions at 1432, 1075 and 690-693 
cm-1 in all the complexes (1 and 2).[37] The 1H-NMR spectra showed in supporting information 
(Figure S1-S3) of the ligand (H2L) and the corresponding complexes recorded in DMSO showed 
all the expected signals in the respective regions. A sharp singlet appeared at δ 11.32 ppm 
corresponding to the presence of hydroxy group in the free ligands which completely 
disappeared in complexes 1 and 2 confirming the involvement of phenolic oxygen in 
coordination.[36,38] A singlet that appeared at δ 9.61 ppm due to the –NH proton for the free 
ligand has also completely disappeared in the spectra of complexes 1 and 2, indicating the 
enolisation and subsequent deprotonation prior to the coordination of imine N  atom.[39] Two 
singlets and one doublet appeared at δ 8.42, δ 8.15 and δ 8.16 ppm  corresponding to the 
presence of the CH=N azomethine proton in the free ligand, complex 2 and complex 1, 
respectively. The aromatic protons present in the ligand and the complexes appeared at δ 6.19-
7.90 ppm.[40] A quartet observed around at δ 2.64-3.28 ppm has been assigned the CH2N group of 
protons in ligand and complexes and a triplet observed at δ 1.02-1.13 ppm has been assigned to 
the terminal methylene group of protons.[38] 
X-ray crystallography 
The molecular structure of complex 1 has been determined by single crystal X-ray diffraction 
study. Details of the data collection and the parameters of refinement process are given in Table 
1. The structure of complex 1 with the atom numbering is depicted in Figure 1. The coordination 
geometry around the palladium ion is distorted square planar in which the ligand acts as 
adianionic tridentate forming a five-member and a six-member chelating ring. The heterocyclic 
hydrazone ligand is bonded to the palladium ion via both phenolateand enolate oxygen atoms 
and the imine nitrogen atom and the fourth coordination site is occupied by triphenylphospine. 
The bond angles are 176.15(4)º for (N1-Pd-P1) and 174.74(5)º for (O1-Pd-O2). 
 
 
Figure 1.Molecular structure of the complex 1 with atomic numbering scheme depicted.    
 Ellipsoids are depicted at the 50 % probability level. 
 
 

































Idendification code Complex 1 
Empirical formula  C34H32N3O3PPd 
Formula weight  667.99 
Temperature/K  100(2)  
Crystal system  Monoclinic  





β/° 112.3125(8)  
γ/° 90 
Volume/Å3 2978.28(8) 
Z  4  
ρcalcg/cm3 1.492 
μ/mm-1 0.717 
F(000)  1368.0  
Crystal size/mm3 0.444 × 0.305 × 0.287 
Radiation  MoKα (λ = 0.71073)  
2θ range for data collection/°  4.192 to 55.834 
Index ranges  
-24 ≤ h ≤ 24,  
-10 ≤ k ≤ 10,  
-27 ≤ l ≤ 27 
Reflections collected  26599  
Rint / Rsigma 0.0298/  0.0268 
Data/restraints/parameters  7128/0/381 
Goodness-of-fit on F2 1.036 
Final R indexes [I>=2σ (I)]  R1 = 0.0243, wR2 = 0.0553 
Final R indexes [all data]  R1 = 0.0303, wR2 = 0.0579 
Largest diff. peak/hole / e Å-3 0.43/-0.32 
DNA binding studies 
In order to determine the ability of any compound to act as a drug, it is important to determine the 
binding of the compound with DNA and this is usually done by electronic absorption titrations. 
Among the possible types of interaction, the intercalative mode of binding usually results in 
hypochromism along with or without a small red or blue shift due to the strong stacking interaction 
between an aromatic chromophore and the base pairs of DNA.[41] But, for a compound that binds 
non-intercalatively or electrostatically with DNA this may result in hyperchromism.[42-44] Hence, we 
measured the absorption spectra of the ligand and complex in the absence and presence of CT-DNA 
and the results are shown in Figure 2. Upon the incremental addition of DNA to the test compounds, 
the following changes were noticed. The nature of the shifts observed and the percentage of 
hypochromism in the absorption bands suggested that they interacted with DNA via intercalative 
mode of binding and complex 1 bound more strongly to DNA than the ligand and complex 2.[45] 
To compare quantitatively the binding strength of the compounds, their intrinsic binding constants 
(Kb) with CT-DNA were determined from the following equation. 
[DNA]/[εa-εf] = [DNA]/[εb-εf] + 1/Kb[εb-εf] 
where [DNA] is the concentration of DNA in base pairs, εa is the extinction coefficient of the 
complex at a given DNA concentration, εf is the extinction coefficient of the complex in free solution 
and εb is the extinction coefficient of the complex when fully bound to DNA. A plot of [DNA]/(εa-εf) 
versus [DNA] gave a slope and an intercept equal to 1/[εa-εf] and 1/Kb[εb-εf] respectively(Figure 3). 
The intrinsic binding constant Kb is the ratio of the slope to the intercept. The values of intrinsic 
binding constants (Kb) were calculated as 1.4311 × 10
6, 2.8331 × 106 and 2.5422 × 106 M-1for the 
ligand and complexes respectively. The observed values of Kb revealed that the ligand and Pd(II) 
complexes bind to DNA via an intercalative mode. These values are very similar to the ones 
reported previously for the intercalative mode of various metallo intercalators.[46,47] From the 
results obtained, it has been found that the ligand and the complexes exhibit almost similar binding 
affinity towards DNA, but complex 1 and 2 showed slightly better affinity. This may be due to the 
chelation of palladium ion with the heterocyclic hydrazone ligand.  
Figure 2.Absorption titration of the ligand (A), complex 1 (B) and Complex 2 (C) with CT-
DNA. 
 
Figure 3.Plot of [DNA] / [εa-εf] versus [DNA]. 
Ethidium bromide fluorescence displacement study 
The binding of any compound to DNA should be proved by another method and in this 
connection; the fluorescent emission of ethidium bromide can be made use of to see whether the 
compound binds to DNA through intercalation.[48] This method is based on the principle that 
there will be a decrease in intensity of the fluorescence of EB bound to DNA as and when the EB 
is replaced by other compounds that bind to DNA. This kind of competitive binding of 
compounds to DNA with EB could provide rich information with regard to the DNA binding 
affinity of any compound for its drug activity. Hence, we carried out the measurement of 
fluorescence spectra of DNA-EB system upon increasing amounts of our test compounds and 
Figure 4 shows the results that we have obtained. The fluorescence quenching spectra illustrated 
that upon increasing the concentration of the compounds a hypochromism has been observed in 
the fluorescence intensity for the ligand and the complexes. The observed decrease in the 
fluorescence intensity clearly indicates that the EB molecules are displaced from their DNA 
binding sites and are replaced by the compounds under investigation.[49] Further, the quenching 
data were analyzed according to the following Stern-Volmer equation, 
I0/I = Kq[Q] + 1 
Where I0 and I represent the emission intensities in the absence and presence of the compound, 
respectively, Kq is the quenching constant, and [Q] is the concentration ratio of the compound. 
The Kq values have been obtained as the slope from the plot of I0/I versus [Q]. The Kq values for 
ligand and complexes have been calculated as 4.12 × 103, 6.85 × 103 and 6.02 × 103 M-1 
respectively which show that the compounds bind to CT-DNA via the intercalation mode.[50] 
 
Figure 4. Fluorescence titration of the DNA-EB system of the ligand (A), complex 1 (B) and 
Complex 2 (C). 
 




 BSA protein binding studies 
In determining the potential of a compound to act as a drug, it is not enough if we know about 
the DNA binding alone but it is equally important to know about its binding to protein as 
proteins are usually the carrier of the drug to the target. Bovine serum albumin (BSA) is a protein 
which has a characteristic fluorescence that can be used to quantify the binding of a compound to 
it. Usually, the quantum yield of fluorescence decreases as and when the test compound binds to 
BSA as a result of a variety of molecular interactions.[51] BSA contains three fluorophores, i.e. 
tryptophan, tyrosine and phenylalanine, and the intrinsic fluorescence of BSA is mainly due to 
tryptophan alone and changes in the emission spectra of tryptophan are common in response to 
protein conformational transitions, subunit associations, substrate binding or denaturation. 
Therefore, we carried out the binding of the synthesized compounds to BSA by examining 
fluorescence spectra. Figure 6 shows the fluorescence emission spectra of BSA after the addition 
of compounds in various concentrations. It can be seen from the spectra that when an increasing 
amount of the test compounds was titrated against a fixed concentration of BSA, the 
fluorescence intensity of BSA decreased gradually with a hypsochromic shift. The observed blue 
shift is mainly due to the binding of compounds with the active site in BSA[52] which is an 
indication for interaction of the ligand and complexes with BSA. The fluorescence quenching 
observed can be described by the Stern-Volmer relation, 
I0/I = 1+ Ksv[Q] 
Where I0and I are the fluorescence intensities of the fluorophore in the absence and presence of 
quencher, Ksv is the Stern-Volmer quenching constant and [Q] is the quencher concentration. 
The Ksv values can be obtained from the slope of a plot of I0/Iversus [Q] (Figure 7(A)). Further, 
when small molecules bind independently to a set of equivalent sites on a macromolecule, the 
equilibrium between free and bound molecules is represented by Scatchard equation.[53,54] 
log[(F0-F)/F] = log K+ nlog [Q] 
where K and n are the binding constant and the number of binding sites, respectively.  A plot of 
log[(F0-F)/F] versus log [Q] [Figure 7(B)] can be used to determine the values of both  K and n, the 
values calculated for the compounds are listed in Table 2. From the values of n, it is inferred that 
there is only one independent class of binding site on BSA that was available for the compounds 
under investigation and a linear relation between the binding constant and number of binding sites 
exists.  
From the Table 2, the calculated value of n is around 1 for all of the compounds, indicating the 
existence of just a single binding site in BSA for all of the compounds. The values of Kbin and 
KSV for all of the compounds suggested that the complexes interact with BSA more strongly than 
the ligand. 
Figure 6.The fluorescence titration of BSA with the ligand (A), complex 1 (B) and Complex 2 
(C). 
 
Figure 7.Stern–Volmer (A) and Scatchard (B) plot of the compounds with BSA. 
 
Table 2. Binding constant (Kbin), quenching constant (KSV), and number of binding sites (n) for 
the interactions of compounds with BSA. 
 
Compound      Kbin (M
-1)        KKSV (M
-1)       n 
        1               4.28 × 102       5.4 × 103           0.79 
        2               5.30× 102         6.95 × 103       0.98 
        3               5.43× 103        6.19 × 103        1.01 
 
The UV-visible absorption spectra of BSA with the ligand and complexes were measured in 
order to find the type of quenching that exists. A simple method to explore the type of quenching 
is UV–visible absorption spectroscopy. The dynamic quenching usually affected only the excited 
state of fluorophores and hence will not change the absorption spectrum. However, if the 
interaction is on the ground state (static), there will be a change in the absorption spectrum of the 
fluorophores. Hence, we measured the UV-vis spectra of BSA in the presence of the compounds 
(Figure 8) which showed  that the absorption intensity of BSA was enhanced as the complexes 
and ligand were added with a little shift in the absorption maxima. [55] 
 
Figure 8. UV absorbance spectra of BSA in the presence of the compounds. 
 
Synchronous fluorescence spectra. 
Fluorescence spectral studies of BSA on the interaction of any compound give information about 
the binding site and binding affinity of the compound.  They do not give any information on the 
micro environmental changes that take place during such interactions, however this is very 
important. A synchronous fluorescence spectrum usually provides information about the 
molecular environment in the vicinity of chromophore molecules in low concentrations under 
physiological conditions which has several advantages such as spectral simplification, bandwidth 
reduction and avoiding different perturbing effects.[56] In synchronous fluorescence spectroscopy, 
the difference between the excitation (λexc) and emission (λemi) wavelength (Δλ = λemi- λexc) 
reflects the spectra of a different nature of chromophores. LargeΔλ values of around 60 nm are 
characteristic of tryptophan residues and a small Δλ value of around 15 nm is characteristic of 
tyrosine.[57] To explore the structural changes of BSA during the addition of the test compounds, 
we measured synchronous fluorescence spectra of BSA with added test compounds at both Δλ = 
15 nm and 60 nm (Figure 9). Upon increasing the concentration of the compounds, it has been 
observed that the intensity of emission decreases without any change in the position of the 
wavelength. These experimental results indicate that the compounds affect the microenvironment 
of both the tryptophan and tyrosine residues more effectively during the binding process and 
synchronous measurements confirmed the effective binding of the ligand and complexes with 
BSA.[58] 
 
Figure 9. The synchronous fluorescence titration of BSA with the compounds. 
 
Cytotoxicity 
The progressive results obtained from the DNA and BSA binding studies for the ligand and their 
palladium(II) complexes have stimulated us to test their ability to inhibit cell growth and induce 
cell death in the selected human cancer cell lines. MTT assay were performed against two A549 
(lung cancer) and MCF7 (breast cancer) cell lines to ascertain the cytotoxicity of the compounds.  
The results obtained have been analyzed by means of cell inhibition expressed as IC50values and 
are shown in Table 3 and Figure 10. From the biological assays of the ligand and Pd(II) 
complexes, it is seen that the complexes exhibit better activities than that of  the ligand against 
the cancer cells which indicate that the chelation of the ligand with the Pd(II) ion is responsible 
for the observed cytotoxic properties of the new complexes. The enhanced cytotoxic properties 
of the complexes over the ligand may be due to the extended planar structure induced by the 
conjugation resulting from the chelation of the heterocyclic hydrazone ligand to the palladium 
ion.[59] However, there is no substantial difference in the cytotoxic activities when triphenyl 
phosphine was replaced by triphenyl arsine in the complexes.  
 










Figure 10. The IC50 values of compounds are depicted against (A549) and (MCF7) cancer cell 
lines. 
Acridine orange /ethidium bromide (AO/EtBr) staining method 
To elucidates the apoptotic activity of synthesized compounds, apoptotic acridine orange 
/ethidium bromide (AO/EtBr)staining fluorescence microscopic analysis was carried out. 
Fluorescence microscopic images of A549 and MCF7 cancer cells in the absence of compounds 
(control) and in the presence of compounds (treated) are shown in Figure 11 which shows that 
the untreated-(a, b, c) A549 and MCF7 cancer cells (control) did not show any significant 
adverse effect compared to the compounds treated-(d, e, f) cancer cells. It can be seen that with 
the addition of compounds to the cancer cells, the green colour of cells are converted into 
yellow/red colour cells which is due to induced apoptosis and the nuclear condensation effect on 
the cells. The morphological changes examined by staining method suggested that the cell death 
mechanism was through apoptosis. 
 
                    IC50 values (μM) 
Compound        A549            MCF7 
Ligand               59± 1.4       63 ± 1.3 
Complex 1        36 ± 1.5       28 ± 1.1 
Complex  2       39 ± 1.2       31 ± 0.9 
Doxorubicin    15 ± 1.2       16 ± 1.3 
Cisplatin          25 ± 2.1       18.7 ± 0.1 
Figure 11.AO/EB stained A549-(A) and MCF7-(B)(a, b, c control and d, e, f are treated with the 
ligand and complexes) cells after 24 h incubation. The yellow or red color cells indicate early 
apoptotic cells. 
Conclusion 
An equimolar reaction of [PdCl2(PPh3)2] and [PdCl2(AsPh3)2] with N'-(4-(diethylamino)-2-
hydroxybenzylidene)furan-2-carbohydrazide ligand resulted in the formation of two new 
palladium complexes. They were characterized by various spectral studies. Based on the 
spectroscopic and single crystal X-ray diffraction studies, a square planar geometry has been 
proposed for the Pd(II) complexes. The ligand coordinated to palladium in dibasic tridentate 
manner by using its phenolateand enolate oxygen atoms and the imine nitrogen atom. The fourth 
position is occupied by triphenylphosphine or triphenylarsine. CT-DNA and binding studies of 
the ligand and Pd(II) complexes suggested that the two complexes bind to CT-DNA more 
strongly than the ligand and the intrinsic fluorescence of BSA was quenched by a static 
quenching mechanism. From the cytotoxic studies of the compounds carried out against A549 
(lung cancer) and MCF7 (breast cancer) cell lines, it has been inferred that the new palladium(II) 
complexes 1 and 2 showed better anticancer activity in both cancer cell lines compared to the 
free ligand. The strong binding affinity and cytotoxicity of the complexes is attributed to the 
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